Given that JMML is a major cause of death in PTPN11-associated NS patients (Strullu et al., 2014) the possibility to treat PTPN11 mutation associated RASopathies with SHP2 inhibitors also needs to be explored, although clinically suitable inhibitors which bind to active SHP2 would be required. The gene discussed is PTPN11; the disease is juvenile myelomonocytic leukemia.